Somatrem
From PeptidePlaza, the free peptide reference · Entry #1071 · Anti-Aging · Sources fetched 2026-09-11 · Editorial standards
Somatrem (also known as Protropin, Protropin (genentech), Methionyl human growth hormone, Somatotropin, N-L-methionyl-) is a anti-aging research peptide. Somatrem, also known as Protropin, is a growth hormone receptor agonist that was FDA approved in 1985.
Somatrem is a growth hormone receptor agonist. It functions by binding to and activating the growth hormone receptor, mimicking the action of naturally occurring growth hormone. This compound was first approved by the FDA in 1985. Research on somatrem includes structural characterization and methods of analysis, as well as comparisons with other somatropin variants. Studies have also explored its bioequivalence with other growth hormone preparations.
1 Mechanism of action
Growth hormone receptor agonist (agonist)
Primary targets: Growth hormone receptor
2 Chemical and physical properties
| CAS number | 82030-87-3 |
|---|---|
| Molar mass | 1009.1 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Growth hormone receptor |
3 Research studies (8)
- Somatrem
(2006) · Review - Somatropin and its variants: structural characterization and methods of analysis
Pharmeuropa bio (2004) - Somatonorm (somatrem) and Genotropin (somatropin): two case studies
Biologicals : journal of the International Association of Biological Standardization (2006) - Bioequivalence of Genotropin and Somatonorm
Acta paediatrica Scandinavica. Supplement (1987) - Human growth hormone produced with recombinant DNA technology: development and production
Acta paediatrica Scandinavica. Supplement (1986) - United Kingdom multicentre clinical trial of somatrem
Archives of disease in childhood (1987) · RCT - Clinical experience with somatrem in growth hormone deficiency
Acta paediatrica Scandinavica. Supplement (1986) · RCT - Present situation worldwide regarding the use and clinical experience of Somatonorm (somatrem)
Acta paediatrica Scandinavica. Supplement (1987) · Review
4 Safety and risk profile
4.1 Regulatory status
Somatrem is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.
5 Frequently asked questions
- What is Somatrem?
- Somatrem, also known as Protropin, is a growth hormone receptor agonist. It is a synthetic form of human growth hormone that was developed using recombinant DNA technology.
- How does Somatrem work?
- Somatrem works as a growth hormone receptor agonist. This means it binds to and activates the growth hormone receptors in the body, thereby mimicking the effects of natural human growth hormone.
- Is Somatrem FDA approved?
- Yes, Somatrem was approved by the FDA in 1985. It has been available for clinical use since then.
- What is Somatrem studied for?
- Somatrem has been studied for its structural characteristics and methods of analysis. Research also includes comparisons with other growth hormone variants and investigations into its bioequivalence with other preparations.
6 References
- Somatrem — compound summary PubChem. View source
- Somatrem — molecule record ChEMBL. View source
- Somatrem — published literature (36 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Somatrem.
Also anti-aging
Leuprolide is a gonadotropin-releasing hormone (GnRH) receptor agonist used in the treatment of advanced prostate cancer and other hormone-sensitive conditions.
Also anti-aging
Triptorelin is a gonadotropin-releasing hormone (GnRH) receptor agonist indicated for the treatment of advanced prostate cancer.
Also anti-aging
Cetrorelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to inhibit premature LH surges in women undergoing controlled ovarian stimulation.
Also anti-aging
Gonadorelin is a synthetic decapeptide that functions as a gonadotropin-releasing hormone (GnRH) receptor agonist. It is used in medicine to stimulate the release of gonadotropins.
Also anti-aging
Nafarelin is a gonadotropin-releasing hormone receptor agonist used in the management of endometriosis and central precocious puberty.
Also anti-aging
Ganirelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to inhibit premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.